leadf
logo-loader
viewErgomed PLC

Ergomed gains as it expands its US footprint in earnings enhancing deal worth up to US$25mln

Chairman, Dr Miroslav Reljanović, said the addition of MedSource builds on the successful acquisition and integration of Ashfield Pharmacovigilance, now PrimeVigilance USA, earlier this year

Ergomed PLC -

Ergomed PLC (LON:ERGO) shares rose on Monday after the firm revealed it has acquired MedSource, a US-based specialist oncology and rare disease contract research specialist, in a deal worth up to US$25mln.

The transaction, which sees the UK group expand its presence in the strategically important US market, will be immediately earnings enhancing.

Practically, it adds 20 new clients and a US$41mln order book.

MedSource’s revenues last year were US$19.3mln, while its underlying earnings (EBITDA) were US$1.3mln.

The company is paying an immediate US$16.2mln in cash and US$1.8mln in paper, followed by up to US$7mln (payable 90% in cash) dependent on 2021 results.

Ergomed chairman, Dr Miroslav Reljanović said the addition of MedSource builds on the successful acquisition and integration of Ashfield Pharmacovigilance, now PrimeVigilance USA, earlier this year.

“We look forward to developing the potential of this new business to offer truly global clinical research services to our international customer base,” he added in a statement.

“We are excited to welcome the MedSource team to Ergomed and are eager to work alongside our new colleagues to leverage our combined expertise in complex therapeutic areas for the benefit of our clients and patients worldwide.

“Looking ahead to 2021 we expect to see continued momentum across the business as we look to increase our footprint in key geographies, and firmly establish Ergomed as a leading global provider of specialist services to the pharmaceutical industry."

Brokers upbeat on deal

In a note commenting on the acquisition, analysts at Shore Capital said:  "We view this as a sensible acquisition given the complementary expertise in rare disease oncology, which are two of the fastest-growing subsegments of the pharmaceutical market.

"In addition, the acquisition will increase Ergomed’s footprint in the strategically important US market and also brings an enlarged order book ($41m, compared with Ergomed’s current order book of £151.4m)."

Meanwhile, analysts at fellow City broker Peel Hunt said: "Today’s announcement is fully aligned with the strategic attractions set out in our recent initiation report, and suggests our bull case, in which we value Ergomed at 1,400p, is starting to play out."

They added: "The deal multiples are favourable vs Ergomed’s trading multiples, even on a trailing (2019) basis and before synergies, and the acquisition is immediately earnings enhancing."

The Peel Hunt analysts repeated a 'buy' rating and 1,100p price target on Ergomed shares, which in morning trade on Monday were 3.5% higher at 1,000p.

 -- Adds broker comment, share price --

 

 

 

Quick facts: Ergomed PLC

Price: 1250 GBX

AIM:ERGO
Market: AIM
Market Cap: £608.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Ergomed reveal 'another good year, with strong top line growth and overall...

Ergomed PLC's (LON:ERGO) Richard Barfield presents the latest trading statement to investors, which reveal 2020 will be ahead of expectations. Barfield says 2020 has been 'another good year, with strong top line growth and overall financial performance'. The company said it expects revenue...

on 27/1/21

2 min read